SCHEMBL5404012

SCHEMBL5404012

Cc1cccc(CN(C)C(=O)c2ccccc2-c2ccccc2C(=O)N(CCC(=O)O)CCc2ccccn2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.43
HCRTR1 O43613 3/20 0.43
HCRTR2 O43614 3/20 0.43
F2 P00734 1/20 0.39
F10 P00742 1/20 0.39
F7 P08709 1/20 0.39
RAF1 P04049 1/20 0.39
MAP2K1 Q02750 1/20 0.39
ALDH1A1 P00352 4/20 0.39
TDP1 Q9NUW8 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
HIF1A Q16665 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PTGFR P43088 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5398682 0.90 KMT2A (0.44) HCRTR1HCRTR2ALDH1A1TDP1CYP2D6
SCHEMBL5401118 0.88 KMT2A (0.39) HCRTR1HCRTR2ALDH1A1TDP1CYP2D6
SCHEMBL5402920 0.88 ALDH1A1 (0.51) KDM4EHCRTR1HCRTR2RAF1MAP2K1
SCHEMBL5405895 0.87 HCRTR1 (0.39) KDM4EHCRTR1HCRTR2ALDH1A1TDP1
SCHEMBL5412315 0.87 KMT2A (0.39) HCRTR1HCRTR2ALDH1A1TDP1NPC1
SCHEMBL5407055 0.87 KMT2A (0.43) ALDH1A1TDP1CYP2D6POLB
SCHEMBL5401457 0.86 HTR2C (0.43) ALDH1A1TDP1
SCHEMBL5401005 0.85 KMT2A (0.48) ALDH1A1TDP1CYP2D6
SCHEMBL5396980 0.85 POLB (0.41) HCRTR1HCRTR2ALDH1A1TDP1NPC1
SCHEMBL5398782 0.84 HCRTR1 (0.42) KDM4EHCRTR1HCRTR2ALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB KDM4E 4680/4885HCRTR1 2878/4885HCRTR2 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.